Home
Scholarly Works
The management of patients with T1 adenocarcinoma...
Conference

The management of patients with T1 adenocarcinoma of the low rectum: An updated decision analysis.

Abstract

645 Background: Patients with T1 adenocarcinoma of the low rectum are faced with a choice between Transanal Local Excision (TLE) and Abdonimoperineal Resection (APR). Fundamentally a tradeoff between quantity and quality of life, this problem is well-suited to decision analysis. A previous decision analysis examined this issue in 1999, but subsequent case series have reported TLE recurrence rates higher than that study considered plausible. Decision analytic techniques have also evolved by incorporating Markov modeling, which better accounts for the temporal aspects of the problem, and microsimulation, which allows for greater flexibility. Methods: We developed a Markov-type microsimulation to evaluate the decision between APR and TLE in T1 adenocarcinoma of the low rectum. We used the software package 'R' and have made all computer code freely available for full transparency. Critical parameters such as transition rates and utilities were elicited by systematic literature reviews and expert opinion. Conflicting values were resolved by weighted averaging and sensitivity analyses. Results: On average, selecting TLE over APR for T1 rectal cancer resulted in a loss of 0.53 years of life expectancy but a gain of 0.97 quality-adjusted life years; hence, TLE was considered the preferable option in the majority of patients. APR was preferred if and only if the patient was unwilling to yield 7% of his or her life expectancy to avoid a permanent stoma. This transition point shifted depending on the anticipated risk of recurrence after TLE. Sensitivity analysis indicated robustness of our findings. Conclusions: Though performing an APR for T1 adenocarcinoma of the low rectum does provide an extra six months of life expectancy, a TLE is the preferable approach for the majority of patients when quality-of-life is taken into consideration. The decision in an individual patient's case can be facilitated by tumour risk-stratification and by ascertaining the patient's willingness to yield life expectancy to avoid a permanent stoma.

Authors

Johnston CF; Tomlinson GA; Temple LKF; Baxter NN

Volume

30

Pagination

pp. 645-645

Publisher

American Society of Clinical Oncology (ASCO)

Publication Date

February 1, 2012

DOI

10.1200/jco.2012.30.4_suppl.645

Conference proceedings

Journal of Clinical Oncology

Issue

4_suppl

ISSN

0732-183X

Labels

View published work (Non-McMaster Users)